News
-
-
-
-
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Intellipharmaceutics International Inc. announces listing transfer from TSX to NEX due to Cease Trade Order, new stock option plan approved. Company specializes in controlled-release drugs -
-
-
-
PRESS RELEASE
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
Intellipharmaceutics International Inc. announces delay in filing annual audited financial statements for the fiscal year ended November 30, 2023, due to applicable Canadian securities laws. Company working to expedite filing for compliance with OSC regulations -
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. issued 1,910,000 common share purchase options to certain eligible individuals under the stock option plan. The options vest over a period of 2 years and expire on February 5, 2034 -
PRESS RELEASE
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Intellipharmaceutics International Inc., a pharmaceutical company, has received conditional approval to list its common shares on the TSX Venture Exchange as a Tier 2 Life Science Issuer. The company's management is working to meet the listing conditions, with expectations for a seamless transition from the Toronto Stock Exchange. Intellipharmaceutics specializes in the research, development, and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix ™ technology offers a multidimensional controlled-release drug delivery platform with various product candidates in the development pipeline. The company has also issued cautionary statements regarding forward-looking information. For further details, refer to the press release.
-
Allied Universal Event Services Professional Winner of Golden State Warriors’ Champion Spotlight Annual Starting 5
-
Viking Capital Announces Closing of Latest 252 Unit Acquisition in Austin - San Antonio Corridor
-
Assays Confirm High-Grade Tarcoola Open Pit Extensions
-
Seismic Survey Reveals Tarcoola Goldfield Architecture
-
OTCQB Trading Secured with DTCC Registration Approval
-
Turkiye Garanti Bankasi A.S.: Prospectus – Summary
-
Turkiye Garanti Bankasi A.S.: Prospectus – Capital Markets Instrument Note
-
EQS-Adhoc: United Internet AG: Non-scheduled, non-cash impairment on Tele Columbus investment
-
Shelly Group: Successful placement of shares with participation of BIT Capital for targeted increase in free float
-
Extraordinary General Meeting of 12 June 2024 - All proposals of the Board of Directors were confirmed by the General Meeting
-
Monthly disclosure of the total number of shares and voting rights - 31/05/2024
-
Combined General Meeting, June 13, 2024
-
Europorte and Kerlink revolutionize freight by launching Track Value, the first logistics application using Kinéis IoT space connectivity
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2024
-
Declaration of voting rights at the end of May 2024